#United States #New York #Securities Fraud #Rosen Law Firm #ADMA Biologics

ADMA Biologics Investors Encouraged to Take Action

In a significant legal development, the Rosen Law Firm is reaching out to investors of ADMA Biologics, Inc. (NASDAQ: ADMA) reminding them of a crucial opportunity. Those who purchased securities of the company between August 9, 2024, and March 25, 2026, are advised to consider joining a securities class action lawsuit that has been initiated by the firm. The deadline for potential lead plaintiffs is August 10, 2026, and it’s a crucial date for those wishing to take an active role in this legal challenge.

Why Should You Join?

The securities class action provides an avenue for affected investors to seek compensation for financial losses incurred during the specified period. Participants in the class action will not incur out-of-pocket fees or costs, as legal representation operates under a contingency fee arrangement. This means that legal fees are only paid from any compensation received, making it a viable option for many investors.

To become a part of this class action lawsuit, individuals are encouraged to visit the Rosen Law Firm's official site or reach out directly by calling Phillip Kim, Esq. toll-free at 866-767-3653 or via email at [email protected]. Joining the class action provides investors with a unified approach to pursue justice collectively.

Legal Insights and Background

The Rosen Law Firm has established credibility in representing investors, focusing particularly on securities class actions. Their notable achievements include ranking first in securities class action settlements against Chinese companies and recovering substantial amounts for investors over the years. In 2019 alone, the firm secured over $438 million for its clients, showcasing its capability to navigate complex securities litigation effectively.

The class action lawsuit against ADMA Biologics stems from allegations that the company made materially false and misleading statements during the class period. Reports suggest that ADMA engaged in a related party transaction that was not disclosed to investors, utilized channel stuffing techniques to artificially inflate perceived revenues, and lacked adequate internal controls over its operations. As such, statements made by the company about its financial health and business prospects were fundamentally flawed, leading to significant investor losses. When the truth about these operations emerged, it triggered considerable financial harm to shareholders.

What’s Next for Investors?

Joining the class action is not automatically guaranteed; interested parties need to act promptly and move to court no later than August 10, 2026, if they wish to serve as lead plaintiffs. The lead plaintiff plays a vital role in directing the litigation on behalf of all class members.

It is essential for investors to carefully select qualified legal counsel to represent them in this significant matter. The Rosen Law Firm advocates for investors to choose a law firm with a proven track record in securities litigation, to ensure their rights are effectively protected. Unlike many firms, Rosen Law Firm operates with deep expertise in this particular area of law, securing its reputation as a trustworthy advocate for investors globally.

As investors consider their options, it’s important to understand that joining the class action does not preclude them from pursuing their own counsel. They have the option to remain absent and take no action at this moment, but their ability to share in any potential recovery will not be dependent on being a lead plaintiff.

Follow for Updates

For ongoing updates and more information regarding the case, investors can follow The Rosen Law Firm on social media platforms like LinkedIn, Twitter, and Facebook. Stay informed to safeguard your investments and maximize potential recovery in this evolving legal landscape.

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com

Note: This article does not serve as legal advice. Interested parties should consult with a qualified attorney to understand their rights and options effectively.